Savara: The Rare Disease Funnel Is Becoming A Commercial Asset

Savara is transitioning from a single-asset biotech to a rare disease commercial infrastructure. Click here to read more on ...
Radio Prague International

Nanoplastics penetrate the lungs’ protective barrier: "We have no way to eliminate them," scientists warn

Czech researchers have discovered that nanoplastics can weaken the lungs’ natural defence system, raising fresh concerns ...
Las Vegas Sun

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) ...
The Manila Times

Oorja Bio Unveils Clinical Data for ORJ-001, a First-in-Class Therapeutic Targeting Alveolar Epithelial Type 2 (AEC2) Cells for Treatment of Idiopathic Pulmonary Fibrosis (IPF)

ORJ-001 achieved therapeutic exposure and was well tolerated in Phase 1 study, supporting company’s plans to initiate Phase 2 clinical trial in IPF patients ...
Le Lézard

Galaxy Receives BitLicense from the New York State Department of Financial Services

Galaxy Digital Inc. (the "Company" or "Galaxy"), a global leader in digital assets and data center infrastructure, today announced that the New York State Department of Financial Services (NYDFS) has ...

Galaxy Entertainment Details Board and Committee Structure

Detailed price information for Galaxy Entmnt Group Ord (GXYEF) from The Globe and Mail including charting and trades.
ahajournals.org

Calcium Signaling in Airway Epithelial Cells: Current Understanding and Implications for Inflammatory Airway Disease

Airway epithelial cells play central roles in protecting the lung against pathogens, allergens, and environmental hazards by releasing inflammatory mediators, surfactant, and mediating mucociliary ...

Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that the FDA has extended the review period for the ...
American Lung Association

Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Autoimmune PAP is the most common form of PAP resulting in the buildup of surfactant in the air sacs of the lungs. There is no cure for this chronic lung condition, but there are treatment options to ...
Medscape

Lung Aeration Patterns in Chest Radiographs Tied to Surfactant Treatment in Premature Infants With Respiratory Distress Syndrome

Computerised chest radiograph analysis revealed that the surfactant treatment led to better aeration in the right lung than in the left lung among infants born extremely preterm with respiratory ...